Theragenics (TGX) Signed Brachytherapy Loading Services Agreement
[Under the three-year agreement, Theragenics will load and package Oncura manufactured brachytherapy seeds in prescription loaded needles, custom strands and other configurations]
Online PR News – 18-December-2012 –Theragenics Corporation (NYSE: TGX) TGX (Theragenics) previously reported it has signed a value-added loading services agreement with Oncura, a unit of GE Healthcare, to provide worldwide brachytherapy loading services to Oncura. Under the three-year agreement, Theragenics will load and package Oncura manufactured brachytherapy seeds in prescription loaded needles, custom strands and other configurations. Oncuras iodine-125 brachytherapy seeds are utilized primarily in the treatment of early stage prostate cancer. This agreement provides for loading services for most Oncura sales of prescription and custom loaded brachytherapy seeds worldwide, which currently includes North America, Europe, Australia and portions of Asia. Theragenics has manufactured radioactive seeds used for the treatment of prostate cancer since 1988 and has performed prescription loading and custom stranding on its internally manufactured brachytherapy seeds since 2005. Theragenics brachytherapy products, including needle loaded and custom stranded packaging, are registered in the United States, Canada and Europe. Theragenics is an ISO 13485 certified medical device manufacturer and provides 100% NIST traceable assay. In addition, Theragenics has been Oncuras exclusive palladium-103 brachytherapy seed supplier since December 2009, providing TheraSeed® for Oncura in prescription loaded and custom stranded configurations. Theragenics Corporation (NYSE: TGX) operates two business segments: its surgical products business and its brachytherapy seed business. The surgical products business (www.cpmedical.com, www.galtmedical.com, www.needletech.com) manufactures and distributes wound closure, vascular access, and specialty needle products. Wound closure products include sutures, needles and other surgical products. Vascular access includes introducers, guidewires and related products. Specialty needles include coaxial, biopsy, spinal and disposable veress needles, access trocars, radiofrequency devices, implanters, introducer products, and other needle-based products. The surgical products segment serves a number of markets and applications, including, among other areas, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. Theragenics brachytherapy business manufactures, markets and distributes seeds used primarily in the minimally invasive treatment of localized prostate cancer. The Companys brachytherapy product line (www.theragenicsbrachy.com) includes its palladium-103 TheraSeed® device and its iodine-125 AgX100 device. The terms Company, we, us, or our mean Theragenics Corporation and all entities included in our consolidated financial statements. For additional information, call our Investor Relations Department at (800) 998-8479 or visit www.theragenics.com. In my opinion this is a stock to watch! (Read Full Disclaimer at http://crwewallstreet.com/disclaimer).
Copyright 2013 Online PR Media | PO Box 5043 | La Quinta, CA 92248